Bill · S. 5297· Senate(119-S-5297)
American Pharmaceutical Security Act
- Introduced
- 8/6/2026
- Last activity
- 8/6/2026 — Read twice and referred to the Committee on Finance.
- Sponsored by
- Adam Schiff
- Cosponsors
- - 0 - 1
- Introduced
- In Committee
What this bill would do
This bill, known as the "American Pharmaceutical Security Act," requires the Administrator of the Centers for Medicare & Medicaid Services to submit a report to Congress. The report must examine how coverage and reimbursement authorities can be used to protect markets for active pharmaceutical ingredients and key starting materials. It specifically looks at protecting the markets of the United States and its allies. Additionally, the report aims to address how to reduce direct and indirect dependence on foreign adversaries for these materials. The Administrator is tasked with providing findings and policy recommendations within one year of the Act's enactment.
Yes· 3 of 16
Does this make the country readier for the next outbreak?+5
Reducing dependence on foreign adversaries for medical ingredients strengthens national pandemic preparedness.
Would business owners be better off under this?+3
Domestic manufacturers may benefit from policies that prioritize domestic sources.
Is this likely to create jobs?+3
The bill's focus on domestic manufacturing could indirectly support job creation in the pharmaceutical sector.
The opposite
Does this make trade with other countries easier?-2
Prioritizing domestic sources over foreign ones could lead to increased trade tensions with current suppliers.
Who it would affect, and how
Potential Positive Impacts for People
-
Protecting Domestic Manufacturing: The report may include recommendations for price floor commitments to support the domestic manufacturing of active pharmaceutical ingredients and key starting materials, which helps protect investments in domestic markets against price manipulation (Section 2, subsection a, and Section 2, subsection b, part 1, part A).
-
Prioritizing Domestic Sources: The report may include recommendations to prioritize domestically manufactured ingredients and materials over those manufactured abroad when a domestic source is available (Section 2, subsection b, part 1, part B).
-
Reducing Dependence on Adversaries: The report aims to find ways to reduce the direct and indirect dependence of the United States on foreign adversaries for essential pharmaceutical ingredients and materials (Section 2, subsection a).
Potential Negative Impacts for People
- No negative impacts or burdens are explicitly identified within the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Business Owners+3Good For Retirees+2Good For Seniors+2Good For Union Workers+2Good For Veterans+2Good For Low Income Households+1Good For Middle Class Households+1Good For People With Disabilities+1
- Economy And Finance
- Improves Consumer Protection+3Increases Job Creation+3Improves Economic Growth+2
- Healthcare
- Improves Pandemic Preparedness+5Improves Healthcare Access+2
- Governance And Ideology
- Improves Government Transparency+2Increases Federal Power+2
- National Security And Foreign Policy
- Improves International Alliances+3Improves International Trade-2
- 8/6/2026
- Read twice and referred to the Committee on Finance.
- 1 Cosponsor added.
- Introduced in Senate
Rick ScottRepublican · Florida